IL42700A - Antibiotic g-52 and method for the production thereof - Google Patents

Antibiotic g-52 and method for the production thereof

Info

Publication number
IL42700A
IL42700A IL42700A IL4270073A IL42700A IL 42700 A IL42700 A IL 42700A IL 42700 A IL42700 A IL 42700A IL 4270073 A IL4270073 A IL 4270073A IL 42700 A IL42700 A IL 42700A
Authority
IL
Israel
Prior art keywords
acid addition
pharmaceutically acceptable
addition salt
acceptable acid
solvate
Prior art date
Application number
IL42700A
Other languages
Hebrew (he)
Other versions
IL42700A0 (en
Original Assignee
Scherico Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scherico Ltd filed Critical Scherico Ltd
Publication of IL42700A0 publication Critical patent/IL42700A0/en
Publication of IL42700A publication Critical patent/IL42700A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20Carbocyclic rings
    • C07H15/22Cyclohexane rings, substituted by nitrogen atoms
    • C07H15/222Cyclohexane rings substituted by at least two nitrogen atoms
    • C07H15/226Cyclohexane rings substituted by at least two nitrogen atoms with at least two saccharide radicals directly attached to the cyclohexane rings
    • C07H15/234Cyclohexane rings substituted by at least two nitrogen atoms with at least two saccharide radicals directly attached to the cyclohexane rings attached to non-adjacent ring carbon atoms of the cyclohexane rings, e.g. kanamycins, tobramycin, nebramycin, gentamicin A2
    • C07H15/236Cyclohexane rings substituted by at least two nitrogen atoms with at least two saccharide radicals directly attached to the cyclohexane rings attached to non-adjacent ring carbon atoms of the cyclohexane rings, e.g. kanamycins, tobramycin, nebramycin, gentamicin A2 a saccharide radical being substituted by an alkylamino radical in position 3 and by two substituents different from hydrogen in position 4, e.g. gentamicin complex, sisomicin, verdamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)

Claims (34)

2028 Israel December 3 , CG/aw C L A I M S
1. A process for the preparation of an antibiotically active substance containing s isomicin and antibiotic G-52 or the pharmaceutically acceptable acid addition salts or solvates thereof or of the single constituents thereof by applying known separation techniques, which comprises cultivating a microorganism of the species Micromonospora zionensis a sample of which has been deposited under NRRL .5466 in an aqueous nutrient medium under aerobic conditions until substantial antibiotic activity is imparted to the said medium and isolating the desired product.
2. Process according to claim 1, wherein the microorganism is cultivated in a nutrient medium containing assimilable sources of at least nitrogen and carbon under submerged aerobic conditions.
3. Process according to claim 1 or 2 ,wherein the cultivation is effected at a temperature of from 23° to 38°C.
4. Process according to claim 3, wherein the temperatures is 35°C.
5. Process according to any of claims 1 to 4, wherein the cultivation is effected at a pH of 6.5 to 8.3. 422072800Is-ra2el -■ ' 4 er 3 , 1975
6. Process according to claim 5, wherein the cultivation is*'- effected at a pH of 7.2.
7. Process according to any one of claims 1 to 6, wherein the antibiotically active product is recovered from the fermentation medium.
8. . Process according to any one of claims 1 to 7, wherein the recovery comprises acidifying the fermentation medium, separating the mycelium therefrom, neutralising the fermentation medium, extracting and isolating the antibiotically active product.
9. Process according to any one on claims 1 to 8, wherein the antibiotically active product prior or subsequent to isolation, is converted into a pharmaceutically acceptable acid addition salt.
10. Process according to claim 8 or 9, wherein antibiotic G-52 having in the free form the stereochemical formula 42700-2 2028 Israel December 3, 1975 CG/aw is isolated in the free form or in the form of a pharmaceutically acceptable acid addition salt or solvate.
11. Process according to any one of claims 8 to 10, wherein sisomicin is isolated in the free form or in the form of a pharmaceutically acceptable acid addition salt or solvate.
12. Process according to any one of claims 8 to 10, wherein a mixture consisting of antibiotic G-52 and sisomicin is isolated in the free form or in the form of a pharmaceutically acceptable acid addition salt or solvate.
13. Process according to any one of claims 9 to 12, wherein the desired product is isolated as the sulfate.
14. Process as claimed in any one of claim 1 to 13, substantially as hereinbefore described and exemplified in any of Examples 1 to 5.
15. An antibiotically active product in the free form or in the form of a pharmaceutically acceptable acid addition salt or solvate, whenever prepared by a process as claimed in any one of claims 1 to 14.
16. Antibiotic G-52 whenever prepared by a process as claimed in claim 10 or 14. ■42700-2 2028 Israel December 3, 1975 CG/aw
17. Sisomicin whenever prepared by a process as claimed in claim 11 or 14.
18. An antibiotically active substance comprising antibiotic G-52, in the free form or in the form of a pharmaceutically acceptable acid addition salt or solvate. i
19. A product according to claim 18, being a solid composition having in its free form a nuclear magnetic resonance spectrum in deuterated water substantially as shown in Figure 1 and an infrared absorption spectrum in mineral oil substantially as shown in Figure 2, in the free form or in the form of a pharmaceutically acceptable acid addition salt or solvate.
20. Antibiotic G-52 having a stereochemical formula substantially as follows: 42700-2 • 2028 Israel December 3, 1975 .. · CG/aw in the free form or in the form of a pharmaceutically acceptable acid addition salt or solvate.
21. An antibiotically active product according to claim 18 comprising antibiotic G-52 and sisomicin in the free form or in the form of a pharmaceutically acceptable acid addition salt or solvate.
22. Product according to any one of claims 18 to 21, said product being the sulfate.
23. Pharmaceutical composition comprising as active ingredient antibiotic G-52 in the free form and/or in the form of pharmaceutically acceptable acid addition salt or solvate, together with a pharmaceutical carrier or excipient.
24. Pharmaceutical composition according to claim 23, wherein the antibiotically active product also contains sisomicin in the free form and/or in the form of a pharmaceutically acceptable acid addition salt or solvate.
25. Composition according to claim 23 or 24 in the form of dosage units.
26. Composition according to any one of claims 23 to 25 in the form of injectable preparations. 42700-2 1 2028 Israel December 3, 1975 ' CG/aw
27. Composition according to claim 23 or 24 in the form of ointments, creams or lotions.
28. Composition according to any one of claims 23 to 25 is shaped form.
29. Composition according to any one of claims 23 to 28 wherein the acid addition salt is the sulfate.
30. Composition according to any one of claims 23 to 29, substantially as described and exemplified herein.'
31. Method for the preparation of an antibiotically active composition as claimed in claim 23, which comprises bringing the active ingredient into a form suitable for therapeutic administration.
32. Method according to claim 31, wherein the active ingredient also contains sisomicin in the free form and/or in the form of a pharmaceutically acceptable acid addition salt or solvate.
33. Method according to claim 31 or 32 which comprises mixing said active ingredient with a pharmaceutical carrier or excipient.
34. Pharmaceutical composition whenever obtained according to any one of claims 31 to 33.
IL42700A 1972-07-14 1973-07-10 Antibiotic g-52 and method for the production thereof IL42700A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27183872A 1972-07-14 1972-07-14

Publications (2)

Publication Number Publication Date
IL42700A0 IL42700A0 (en) 1973-10-25
IL42700A true IL42700A (en) 1976-07-30

Family

ID=23037307

Family Applications (1)

Application Number Title Priority Date Filing Date
IL42700A IL42700A (en) 1972-07-14 1973-07-10 Antibiotic g-52 and method for the production thereof

Country Status (22)

Country Link
JP (1) JPS5713278B2 (en)
AR (1) AR199112A1 (en)
AT (1) ATA607973A (en)
BE (1) BE802185A (en)
BG (1) BG22409A3 (en)
CA (1) CA984774A (en)
CH (1) CH584754A5 (en)
DD (2) DD107483A5 (en)
DE (1) DE2334923A1 (en)
DK (1) DK131791C (en)
FI (1) FI50254C (en)
FR (1) FR2247220B1 (en)
GB (1) GB1424114A (en)
HU (1) HU175176B (en)
IE (1) IE38063B1 (en)
IL (1) IL42700A (en)
LU (1) LU67985A1 (en)
NL (1) NL7309610A (en)
PH (1) PH11419A (en)
PL (1) PL87638B1 (en)
SE (1) SE390541B (en)
ZA (1) ZA734694B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62150190U (en) * 1986-03-17 1987-09-22
JPS6311876U (en) * 1986-07-09 1988-01-26
JPS63112078U (en) * 1987-01-08 1988-07-19

Also Published As

Publication number Publication date
DD107483A5 (en) 1974-08-05
GB1424114A (en) 1976-02-11
ZA734694B (en) 1974-06-26
FI50254B (en) 1975-09-30
FR2247220A1 (en) 1975-05-09
IL42700A0 (en) 1973-10-25
DK131791C (en) 1976-02-02
FI50254C (en) 1976-01-12
DE2334923A1 (en) 1974-01-24
PH11419A (en) 1978-01-09
DK131791B (en) 1975-09-01
IE38063B1 (en) 1977-12-21
SE390541B (en) 1976-12-27
IE38063L (en) 1974-01-14
JPS5713278B2 (en) 1982-03-16
HU175176B (en) 1980-05-28
LU67985A1 (en) 1973-09-13
ATA607973A (en) 1977-11-15
BG22409A3 (en) 1977-02-20
NL7309610A (en) 1974-01-16
BE802185A (en) 1974-01-11
FR2247220B1 (en) 1976-12-31
AU5797673A (en) 1975-01-16
JPS4955895A (en) 1974-05-30
PL87638B1 (en) 1976-07-31
CH584754A5 (en) 1977-02-15
DD113169A5 (en) 1975-05-20
CA984774A (en) 1976-03-02
AR199112A1 (en) 1974-08-08

Similar Documents

Publication Publication Date Title
US3928387A (en) Antibiotic 1745A/X and methods for the production thereof
JPS5910798B2 (en) New method for producing rifamycins
US2928844A (en) Celesticetin, its salts and method of preparation
GB1339032A (en) Rabelomycin and processes for its production
US4705688A (en) Antibiotic LL-E19020 α and β
GB1357538A (en) New antibiotic
US4554162A (en) CL-1724 Antibiotic compounds, their production and use
JPS61216692A (en) Cl-1577-b4 compound and its production
US2990329A (en) Preparation of ristocetin a salts
IL42700A (en) Antibiotic g-52 and method for the production thereof
US3699121A (en) Antibiotic
DE1620639A1 (en) Process for the preparation of 9-ss-D-ribofuranosyl-7-deazapurine-3 ', 5'-cyclophosphates
US3592925A (en) Antibiotics ah272alpha2 and ah272beta2 and process for producing same
EP0245012A1 (en) Method for the preparation of 14-hydroxy-6-0-methyl-erythromycin A
US3465079A (en) Antibiotic sl 1846
US2916483A (en) Methymycin
CA1046965A (en) Naphthyridinomycin antibiotics from streptomyces
US3692777A (en) 5h-pyrrolo {8 2,1-c{9 {8 1,4{9 {0 benzodiazepin-5-ones
US3089816A (en) Lemacidine and process for its manufacture
US3264195A (en) Process for the preparation of septacidin and derivatives
US4216206A (en) Antibiotics S 53210/A-I, S 53210/A-II and S 53210/A-III
US3803307A (en) Antibiotic sl 21429
US3074855A (en) Process for preparing naramycin a and its isomer
US3616238A (en) Method of preparing (+)-5'-hydroxygriseofulvin
US3328248A (en) Antibiotic product and process of producing same